logo_new@0,75x
  • Glycotest
  • About us
    • Management Team and Board
    • Scientific and Medical Advisors
    • Glycotest Investor Presentation
  • Technology
    • Clinical Data
    • Intellectual Property
  • News
  • Contact us
glycotest_logo
logo_new@0,75x
  • Glycotest
  • About us
    • Management Team and Board
    • Scientific and Medical Advisors
    • Glycotest Investor Presentation
  • Technology
    • Clinical Data
    • Intellectual Property
  • News
  • Contact us

Glycotest’s Patent Portfolio Covering Detection of Serious Liver Disease Expanded by Grant of European Patent.

January 13, 2021
-
News
-
No comments
-
Posted by glycotest

Leave a Comment

Your feedback is valuable for us. Your email will not be published.
Cancel Reply

Please wait...
Submit Comment

Related News

Other posts that you should not miss.

More than 50 Glycotest Fucosylated Biomarkers Protected through Grant of New US Patent.

November 3, 2020
-
News
Read More →
Posted by glycotest
1 MIN READ

Glycotest, Inc. Receives $3 Million Second Tranche of $10 Million Series A Financing

November 21, 2019
-
News
New York, NY—November 21, 2019.  Glycotest, Inc., a diagnostics company commercializing new and unique blood tests for life threatening liver cancers and fibrosis–cirrhosis, announced today that the Company…
Read More →
Posted by Webmaster
3 MIN READ

Glycotest is developing a new Test for Detecting Early Stage Liver Cancer with the revolutionary approach of using Glycoproteins as Biomarkers – CEOCFO Magazine

September 3, 2019
-
News
Glycotest19-CEOCFOMagazine-Interview.pdf
Read More →
Posted by Webmaster
1 MIN READ

GET IN TOUCH

Give Us A Call

+1 484-431-3483

Send Us A Message

info@glycotest.com

Copyright© All Rights Reserved
Website Designed & Developed by Jason and Company
Glycotest’s Patent Portfolio Covering Detection of Serious Liver Disease Expanded by Grant of European Patent. | Glycotest Diagnostics